IL6 and melanoma: In examining human stage 3 melanoma patient populations retrospectively, Lacreusette et al. [152] found that relapse-free survival correlated to sensitivity to OSM or IL-6 antiproliferative effects but not to responses to other cytokines including IFNγ or TNFα.